2 June 2022 - Byooviz, priced 40% lower than Lucentis, provides an equally effective and more affordable treatment option to patients suffering from retinal disorders.

Biogen and Samsung Bioepis today announced that Byooviz (ranibizumab-nuna), a biosimilar referencing Lucentis (ranibizumab)i has been launched in the United States. 

Health care provider engagement, promotional activity, collaborations with professional societies and patient advocacy groups have commenced and Byooviz will be commercially available on 1 July 2022, through major distributors across the U.S. 

Read Biogen press release